Shares of Zydus Lifesciences hit a 52-week high of Rs 680 on 18 December after the company announced receiving final approval from the USFDA (United States Food and Drug Administration) to manufacture and market Lacosamide Tablets USP, 50 mg, 100 mg, 150 mg, and 200 mg.

Lacosamide is used to treat partial-onset seizures and can also be used with other medicines to treat primary generalised tonic-clonic seizures.

The drug will be manufactured at the company’s formulation manufacturing facility in Moraiya, Ahmedabad.

The company now has 384 approvals and has filed for more than 440 ANDAs (abbreviated new drug applications) since the commencement of the filing process in the fiscal year 2003-04.

On 15 December, the company received approval from the USFDA to market Darunavir Tablets, which are used for the treatment of HIV-1 infection.

On 11 December, the company also announced that Zydus Worldwide DMCC, its wholly-owned subsidiary, entered into a licensing pact with South Korea’s Daewoong Pharmaceutical Co Ltd to co-develop and commercialise a generic version of Leuprolide Acetate.

At 1:05 pm, the shares of Zydus Lifesciences were trading 3.96% higher at Rs 671.50 on NSE.